Kyntra Bio (KYNB) Profit After Tax (2014 - 2026)

Kyntra Bio has reported Profit After Tax for 13 years, with the latest figure at -$15.1 million in Q1 2026.

• Quarterly Profit After Tax fell 426.19% year-over-year to -$15.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163.7 million (up 2580.66% YoY) and the FY2025 annual result came in at $183.5 million, up 485.57% from the prior year.
• Profit After Tax slipped to -$15.1 million in Q1 2026 per KYNB's latest filing, from -$14.2 million in the prior quarter.
• Over five years, Profit After Tax peaked at $200.6 million in Q3 2025 and troughed at -$91.6 million in Q3 2022.
• A 5-year average of -$26.9 million and a median of -$49.0 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2025 and 2026: Profit After Tax jumped 515.46% in 2025, then sank 426.19% in 2026.
• Over 5 years, Profit After Tax stood at -$66.2 million in 2022, then grew by 15.03% to -$56.2 million in 2023, then jumped by 272.24% to $96.9 million in 2024, then slumped by 114.68% to -$14.2 million in 2025, then decreased by 6.41% to -$15.1 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$15.1 million, -$14.2 million, and $200.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.